Littérature scientifique sur le sujet « CD20 antibodies »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « CD20 antibodies ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "CD20 antibodies"
Fuh, Franklin, Reina Fuji, Kirsten A. Poon, Dongwei Li, Clarissa David, Quyen Nguyen, Kathy Howell et al. « Pharmacodynamic Effects of Administration of Maytansine Conjugated Anti-CD22 Monoclonal Antibodies to Cynomolgus Monkeys ». Blood 112, no 11 (16 novembre 2008) : 4996. http://dx.doi.org/10.1182/blood.v112.11.4996.4996.
Texte intégralDuperray, C., J. M. Boiron, C. Boucheix, J. F. Cantaloube, T. Lavabre-Bertrand, M. Attal, J. Brochier, D. Maraninchi, R. Bataille et B. Klein. « The CD24 antigen discriminates between pre-B and B cells in human bone marrow. » Journal of Immunology 145, no 11 (1 décembre 1990) : 3678–83. http://dx.doi.org/10.4049/jimmunol.145.11.3678.
Texte intégralRymkiewicz, Grzegorz, Renata Woroniecka, Katarzyna Blachnio, Barbara Pienkowska-Grela et Jan Walewski. « Flow Cytometry and Fluorescence In Situ Hybridization Are Methods of Choice for Routine Diagnosis of Mantle Cell Lymphoma. » Blood 106, no 11 (16 novembre 2005) : 4659. http://dx.doi.org/10.1182/blood.v106.11.4659.4659.
Texte intégralLones, Mark, et Ivan Kirov. « Cell Surface Targets for Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents. » Blood 104, no 11 (16 novembre 2004) : 4544. http://dx.doi.org/10.1182/blood.v104.11.4544.4544.
Texte intégralPaiva, Aldair Sousa, Alessandra Suelen Jardim Silva, Victor lima Soares, Gustavo Henrique de Medeiros Oliveira, Lenilton Silva DA Silva Júnior, Hugo Henrique de Freitas Ferreira, Rodrigo Villar Freitas et al. « Importance of Flow Cytometry in the Differential Diagnosis of Hairy Cell Leukemia in the State of Rio Grande Do Norte, Brazil ». Blood 136, Supplement 1 (5 novembre 2020) : 14–15. http://dx.doi.org/10.1182/blood-2020-143225.
Texte intégralGeisler, CH, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B. Lund, H. Nielsen, T. Plesner, K. Thorling et E. Andersen. « Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia ». Blood 78, no 7 (1 octobre 1991) : 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.1795.
Texte intégralGeisler, CH, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B. Lund, H. Nielsen, T. Plesner, K. Thorling et E. Andersen. « Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia ». Blood 78, no 7 (1 octobre 1991) : 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.bloodjournal7871795.
Texte intégralEscribano, Luis, Alberto Orfao, Jesús Villarrubia, Beatriz Díaz-Agustín, Carlos Cerveró, Agustín Rios, José L. Velasco, Juana Ciudad, José L. Navarro et Jesús F. San Miguel. « Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples ». Analytical Cellular Pathology 16, no 3 (1998) : 151–59. http://dx.doi.org/10.1155/1998/341340.
Texte intégralWeitzman, James, Monica Betancur, Laurent Boissel, Arthur P. Rabinowitz et Hans Klingemann. « Variable Contribution of Different Monocloncal Antibodies to NK Cell-Mediated ADCC Against Primary CLL Cells. » Blood 110, no 11 (16 novembre 2007) : 4715. http://dx.doi.org/10.1182/blood.v110.11.4715.4715.
Texte intégralKusakabe, Manabu, Guillermo Simkin, Justin Meskas, Chaoran Zhang, Daisuke Ennishi, Merrill Boyle, David W. Scott et al. « Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma ». Blood 124, no 21 (6 décembre 2014) : 2976. http://dx.doi.org/10.1182/blood.v124.21.2976.2976.
Texte intégralThèses sur le sujet "CD20 antibodies"
Eve, Heather E. « Lenalidomide and the new-generation anti-CD20 antibodies in mantle cell lymphoma ». Thesis, Exeter and Plymouth Peninsula Medical School, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.573119.
Texte intégralWalshe, Claire Anne. « Signalling cascades induced by type I and II anti-CD20 monoclonal antibodies ». Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436973.
Texte intégralShan, Daming. « Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies / ». Thesis, Connect to this title online ; UW restricted, 1998. http://hdl.handle.net/1773/5682.
Texte intégralDIAS, CARLA R. de B. R. « Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re ». reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.
Texte intégralMade available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0
Tese (Doutoramento)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
Nolan, David Francis Luke. « The synergistic interaction between CD20 monoclonal antibodies and histone deacetylase inhibitors in B cell Non Hodgkin's Lymphoma ». Thesis, University of Southampton, 2010. https://eprints.soton.ac.uk/162661/.
Texte intégralReslan, Lina. « Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia ». Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10346/document.
Texte intégralCD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro. AnnexinV staining demonstrated induction of apoptosis after exposure torituximab or GA101. Unlike rituximab, GA101 induced a reduction of the mitochondrial transmembranepotential, an effect which could be partially inhibited by cyclosporin A and which was partially caspasedependent.GA101 was also found to induce the production of Reactive Oxygen Species. Analysis of pro- andanti-apoptotic protein content after exposure to antibodies demonstrated a strong degree of heterogeneity between samples. Bax underwent conformational activation and mitochondrial translocation upon exposure toantibodies in a caspase-independent manner. GA101 but not rituximab induced cleavage of caspase-8, -9 and -3.By transfecting CLL cells with anti-Bcl-xL siRNA using a sonoporation method, we found that reduction of BclxLcontent was associated with increased sensitivity to these antibodies. Our results suggest that apoptoticsignalization pathways differ between rituximab and GA101 with a greater involvement of the mitochondrialpathway for GA101. Inhibition of Bcl-xL could constitute an approach to sensitize CLL cells to the apoptoticeffects of anti-CD20 antibodies
Spasevska, Ivana. « The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies ». Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1304/document.
Texte intégralAnti-CD20 monoclonal antibodies (mAbs) are an essential component of the treatment of patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). They mediate their antitumor effects by activating the immune system or by direct apoptotic signaling in target cells. In a previous preclinical study, we showed that treatment with anti-CD20 mAbs, rituximab and GA101, resulted in upregulated expression of early growth factor 1 (EGR-1) (Dalle et al. 2011). EGR-1 is a calcium (Ca2+) regulated transcription factor and CD20 is hypothesized to regulate transmembrane Ca2+ flux. Therefore, we aimed to assess the role of EGR-1 and Ca2+ flux in the cytotoxic activity of anti-CD20 mAbs. We have shown that EGR-1 expression is rapidly upregulated in CD20+ cells following rituximab and GA101 exposure. Decreasing EGR-1 expression by shRNA abolishes the direct cytotoxic effect of GA101 both in vitro and in vivo, indicating that EGR-1 is required for CD20-mediated cell death. Additionally, the overexpression of EGR-1 enhances the cytotoxic activity of GA101 both in vitro and in vivo. Furthermore, our results indicate that anti-CD20 mAbs induce calcium influx. Blocking the Ca2+ flux with calcium channel blockers (CCB) abolishes EGR-1 induction and impaires the GA101 efficacy in vivo and ex vivo in CLL blood samples. More importantly, our data indicate that patients receiving CCBs and anti-CD20 therapy have worst progression free survival and overall survival. In conclusion we have identified EGR-1 as a potential biomarker to predict response to anti-CD20 therapy. We demonstrated that co-treatement with CCBs negatively impacts the outcome of patients receiving anti-CD20 mAbs
AKANJI, AKINKUNMI G. « Estudo de marcação com iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma nao-hodgkin ». reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11488.
Texte intégralMade available in DSpace on 2014-10-09T14:01:38Z (GMT). No. of bitstreams: 0
Dissertação (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP
Nishida, Michio. « Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions ». Kyoto University, 2008. http://hdl.handle.net/2433/124332.
Texte intégralAKANJI, AKINKUNMI G. « Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos ». reponame:Repositório Institucional do IPEN, 2013. http://repositorio.ipen.br:8080/xmlui/handle/123456789/28021.
Texte intégralMade available in DSpace on 2017-11-17T17:17:04Z (GMT). No. of bitstreams: 0
Linfomas são cânceres que se iniciam a partir da transformação maligna de um linfócito no sistema linfático. Os linfomas são divididos em duas categorias principais: os linfomas de Hodgkin e todos os outros linfomas, denominados linfomas não-Hodgkin (LNH). Os pacientes com LNH são comumente tratados com radioterapia apenas ou combinada com quimioterapia utilizando-se de anticorpo monoclonal anti-CD20, principalmente o rituximab (MabThera®). O uso de anticorpos monoclonais (Acm) conjugados à quelantes bifuncionais radiomarcados com radionuclídeos metálicos ou lantanídeos é uma realidade de tratamento para portadores de LNH pelo princípio de radioimunoterapia (RIT). Este estudo concentrou-se nas condições de conjugação do anticorpo monoclonal rituximab (MabThera®) com grupamentos quelantes bifuncionais DOTA e DTPA. Na marcação dos Acm conjugados com lutécio-177, foram estudadas as condições de pré-purificação do Acm, condições de conjugação, determinação de número de quelantes acoplados à molécula do anticorpo, purificação do anticorpo conjugado, radiomarcação do anticorpo conjugado, com lutécio-177, purificação do anticorpo marcado, a ligação específica in vitro dos compostos marcados às células Raji, e distribuição biológica em camundongos BALB/c sadios. As três metodologias empregadas na pré-purificação do anticorpo (diálise, cromatografia de exclusão molecular com coluna Sephadex G-50 e ultrafiltração) demonstram-se eficientes e proporcionaram recuperação da amostra superior a 90%. A metodologia de ultrafiltração foi considerada a mais simples e prática, podendo ser aplicada a procedimentos rotineiros de produção de radiofármacos. Além disso, proporcionou a recuperação final de amostra de 97% em microlitros. Nas conjugações do anticorpo com os quelantes DOTA e DTPA em razões molares diferentes do Acm:quelante, observou-se número de grupamentos quelantes acoplados à molécula do Acm proporcional à razão molar estudada. Quando foi avaliada a influência de condições diferentes de conjugação no número de quelantes acoplados à molécula do Acm, não foram observadas diferenças significativas, com resultados de pureza radioquímica (PR) inferior a 80% em todas as condições estudadas. Na comparação de métodos de purificação do Acm conjugado, a abordagem inédita apresentada neste estudo, na qual a cromatografia de exclusão molecular foi combinada com a ultrafiltração resultou em maior eficiência na purificação e preservação da estrutura do anticorpo. Nos estudos de radiomarcação do anticorpo conjugado com DOTA e DTPA, os imunoconjugados de DTPA apresentaram, de forma geral, maior eficiência de marcação com resultados reprodutíveis quando comparados com os imunoconjugados de DOTA, considerando-se as diferentes razões molares utilizadas. As metodologias cromatográficas empregadas no controle de pureza radioquímica do composto radiomarcado proporcionaram a discriminação das diferentes espécies radioquímicas no meio de marcação. A metodologia de purificação do composto conjugado e radiomarcado utilizada proporcionou a obtenção de compostos com alta pureza radioquímica, 97,4±1,3% (DOTA 1:50) e 98,7±0,2% (DTPA 1:50). Nos estudos de ligação específica às células tumorais Raji, o anticorpo conjugado com quelante DTPA nas razões molares de 1:50 e 1:20 apresentaram perfil semelhante de ligação, com aumento da porcentagem de ligação específica proporcional à concentração celular, enquanto que o imunoconjugado na razão molar de 1:10 apresentou alta porcentagem de ligação não específica. Os resultados obtidos nos estudos de biodistribuição in vivo do anticorpo conjugado e radiomarcado nem sempre se mostraram compatíveis com a biodistribuição de anticorpos radiomarcados íntegros. No caso do quelante DOTA, o imunoconjugado obtido a partir da razão molar 1:20, apresentou melhores características de biodistribuição. No caso do quelante DTPA, a razão molar utilizada pareceu refletir diretamente no clareamento sanguíneo do anticorpo e todas as razões molares utilizadas apresentaram instabilidade in vivo.
Tese (Doutorado em Tecnologia Nuclear)
IPEN/T
Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP
Livres sur le sujet "CD20 antibodies"
Cho, William Chi Shing. Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal. Elsevier Science & Technology Books, 2023.
Trouver le texte intégralDörner, Thomas, et Peter E. Lipsky. Cellular side of acquired immunity (B cells). Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0050.
Texte intégralChapitres de livres sur le sujet "CD20 antibodies"
Lindorfer, Margaret A., Joost M. Bakker, Paul W. H. I. Parren et Ronald P. Taylor. « Ofatumumab (Arzerra®) : a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity ». Dans Handbook of Therapeutic Antibodies, 1733–74. Weinheim, Germany : Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch63.
Texte intégralKlein, Christian, Marina Bacac, Pablo Umaña et Michael Wenger. « Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma ». Dans Handbook of Therapeutic Antibodies, 1695–732. Weinheim, Germany : Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch62.
Texte intégralJacene, Heather A., et Richard L. Wahl. « Non-Hodgkin Lymphoma : Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”) ». Dans Therapeutic Nuclear Medicine, 505–25. Berlin, Heidelberg : Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/174_2013_943.
Texte intégralNewton, Dianne L., Luke H. Stockwin et Susanna M. Rybak. « Anti-CD22 Onconase : Preparation and Characterization ». Dans Therapeutic Antibodies, 425–43. Totowa, NJ : Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_22.
Texte intégralvan de Donk, Niels W. C. J., et Eugen Dhimolea. « Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies ». Dans Handbook of Therapeutic Antibodies, 1417–44. Weinheim, Germany : Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch49.
Texte intégralElluru, Sri Ramulu, Srini V. Kaveri et Jagadeesh Bayry. « Regulation of Human Dendritic Cell Functions by Natural Anti-CD40 Antibodies ». Dans Methods in Molecular Biology, 47–54. New York, NY : Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0669-7_5.
Texte intégralReinhold, D., T. Kähne, M. Täger, U. Lendeckel, F. Bühling, U. Bank, S. Wrenger, J. Faust, K. Neubert et S. Ansorge. « The Effect of Anti-CD26 Antibodies on DNA Synthesis and Cytokine Production (IL-2, IL-10 and IFN-γ) Depends on Enzymatic Activity of DP IV/CD26 ». Dans Advances in Experimental Medicine and Biology, 149–55. Boston, MA : Springer US, 1997. http://dx.doi.org/10.1007/978-1-4757-9613-1_19.
Texte intégralTurco, Maria Caterina, Mario De Felice, Soo Young Yang, Soldano Ferrone et Salvatore Venuta. « Differential Modulation by Anti-HLA Class I Monoclonal Antibodies of T Cell Proliferation Induced via CD2 and CD3 Pathways ». Dans Immunobiology of HLA, 147–50. Berlin, Heidelberg : Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-662-39946-0_38.
Texte intégralFerrone, S., M. De Felice, M. C. Turco, L. Corbo et S. Venuta. « Effect of Anti-HLA Class I Monoclonal Antibodies on the Proliferation of T Cells Induced by PHA-P. Comparison with the Effect on T Cell Activation via the CD2 and CD3 Pathways ». Dans MHC + X, 100–106. Berlin, Heidelberg : Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-74026-8_16.
Texte intégralBernard, Alain, Philippe Brottier, Eric Georget, Virginia Lepage et Laurence Boumsell. « The Epitopic Dissection of the CD2 Defined Molecule : Relationship of the Second Workshop Antibodies in Terms of Reactivities with Leukocytes, Rosette Blocking Properties, Induction of Positive Modulation of the Molecule, and Triggering T Cell Activation ». Dans Leukocyte Typing II, 53–66. New York, NY : Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-8587-5_4.
Texte intégralActes de conférences sur le sujet "CD20 antibodies"
Tent, Michiel. « Chronic active MS lesions respond poorly to anti-CD20 antibodies ». Dans ECTRIMS Congress 2022, sous la direction de Hans-Peter Hartung. Baarn, the Netherlands : Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/45da9aa4.
Texte intégralMoskalets, O. V. « The incidence of anti-rituximab antibodies in patients with chronic lymphocytic leukemia ». Dans Global science. Development and novelty. L-Journal, 2020. http://dx.doi.org/10.18411/gsdn-25-12-2020-05.
Texte intégralXu, Wei, Johannes Sam, Mario Perro, John Challier, Christina Claus, Stanford Chen, Claudia Ferrara Koller et al. « Abstract 957 : Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-957.
Texte intégralMoskalets, O. V. « Anti-rituximab antibodies in refractory / relapsing cases of chronic lymphocytic leukemia ». Dans General question of world science. L-Journal, 2020. http://dx.doi.org/10.18411/gq-30-11-2020-02.
Texte intégralGupta, Pankaj, Edmund A. Rossi, David M. Goldenberg et Chien-Hsing Chang. « Abstract 4572 : Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4572.
Texte intégralSpasevska, Ivana, Jade Villé, Kamel Chettab, Eva-Laure Matera et Charles Dumontet. « Abstract 4594 : Induction of apoptosis by anti-CD20 antibodies requires the induction of EGR-1 and calcium influx ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4594.
Texte intégralPyrzynska, Beata, Abdessamad Zerrouqi, Michal Dwojak, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon et al. « Abstract B17 : FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies ». Dans Abstracts : AACR Special Conference on Tumor Immunology and Immunotherapy ; October 1-4, 2017 ; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b17.
Texte intégralZerrouqi, Abdessamad, Beata Pyrzynska, Michal Dwojak, Nina Miazek, Piotr Zapala, Jakub Golab et Magdalena Winiarska. « Abstract B27 : B-cell lymphoma response to anti-CD20 antibodies based therapies is tightly modulated by FOXO1-mediated MS4A1 gene transcription ». Dans Abstracts : AACR Special Conference on Tumor Immunology and Immunotherapy ; October 1-4, 2017 ; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b27.
Texte intégralZerrouqi, Abdessamad, Nina Miazek-Zapala, Anna Torun, Piotr Zapala, Jakub Golab, Magdalena Winiarska et Beata Pyrzynska. « Abstract LB-261 : Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-261.
Texte intégralZerrouqi, Abdessamad, Nina Miazek-Zapala, Anna Torun, Piotr Zapala, Jakub Golab, Magdalena Winiarska et Beata Pyrzynska. « Abstract LB-261 : Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-lb-261.
Texte intégralRapports d'organisations sur le sujet "CD20 antibodies"
Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis : a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, juin 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.
Texte intégralLin, Zhijuan, Xing Chen, Long Liu, Zhifeng Li et Bing Xu. Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma : A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, novembre 2021. http://dx.doi.org/10.37766/inplasy2021.11.0111.
Texte intégral